Literature DB >> 17529868

Bloodstream infection caused by Stenotrophomonas maltophilia in children.

Jessica Kagen1, Theoklis E Zaoutis, Karin L McGowan, Xianqun Luan, Samir S Shah.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia, a multidrug resistant Gram-negative pathogen, has become a more frequent cause of bloodstream infections (BSI). Little is known about development of S. maltophilia bacteremia in children. The objective of this study was to define risk factors and outcomes associated with S. maltophilia BSI in children.
METHODS: This was a retrospective case-control study conducted at The Children's Hospital of Philadelphia between January 1, 2000 and July 31, 2005. All patients with S. maltophilia BSI were compared with a random sample of patients with non-Stenotrophomonas Gram-negative rod BSI.
RESULTS: Fifty-one cases and 103 control subjects were included in the study. The median patient age was 2 years (interquartile range: 1 day-8.5 years). Patients with S. maltophilia BSI were significantly more likely to have a malignancy and be coinfected with other organisms than those with other Gram-negative rod infections. On multivariate analysis, patients with S. maltophilia BSI were more likely to develop their infection in the home setting (adjusted OR, 4.18; 95% CI: 1.44-12.16; P = 0.009). Additionally, prior exposure to trimethoprim-sulfamethoxazole, receipt of steroids or other immunosuppressive medication in the 30 days preceding infection and black race were associated with the development of S. maltophilia BSI.
CONCLUSIONS: Patients with Stenotrophomonas maltophilia BSI are more likely to have a polymicrobial infection and develop their infection in the home setting compared with patients with BSI caused by other Gram-negative rods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17529868     DOI: 10.1097/INF.0b013e318059c285

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

1.  Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Pneumonia in a Neonate.

Authors:  Karen Leask Ryan; Deonne Dersch-Mills; Deborah Clark
Journal:  Can J Hosp Pharm       Date:  2013-11

Review 2.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

3.  Dengue co-infection in a blood stream infection caused by Stenotrophomonas maltophilia: A case report.

Authors:  Sreenivasan Srirangaraj; Arunava Kali; Sivaranjini Vijayan
Journal:  Australas Med J       Date:  2014-11-30

Review 4.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

5.  Non-fermentative Gram-negative rods bacteremia in children with cancer: a 14-year single-center experience.

Authors:  D Averbuch; C Avaky; M Harit; P Stepensky; I Fried; T Ben-Ami; V Temper; Y Peled; H Troen; R Masarwa; W Abu Ahmad; M Weintraub; S Revel-Vilk; D Engelhard
Journal:  Infection       Date:  2017-02-15       Impact factor: 3.553

6.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Nikki Jahnke; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2020-03-18

7.  The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study.

Authors:  Bin Cai; Glenn Tillotson; Darrin Benjumea; Patrick Callahan; Roger Echols
Journal:  Open Forum Infect Dis       Date:  2020-04-22       Impact factor: 3.835

8.  Twitching motility of Stenotrophomonas maltophilia under iron limitation: In-silico, phenotypic and proteomic approaches.

Authors:  Kalidasan V; Vasantha Kumari Neela
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.